Chronic myelogenous leukemia is a myeloproliferative disorder. It is characterized by a
biphasic or triphasic clinical course in which a benign chronic phase is followed by …

Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of
chronic myeloid leukemia (CML) with interferon-α (IFN-α), but CCgRs are rare. The mean …

Tyrosine kinase inhibitors (TKIs) elicit high response rates among individuals with kinase-
driven malignancies, including chronic myeloid leukemia (CML) and epidermal growth factor …

Background Transplantation of blood or bone-marrow stem cells is the treatment of choice
for selected patients with chronic myeloid leukaemia (CML). Transplantation is used with …

OBJECTIVE: At present, no dynamic quantitative models of stem cell organization are
available that fulfill all criteria of the prevalent functional definition of hematopoietic stem …

This study investigated the feasibility of allogeneic (alloSCT) and autologous stem cell
transplantation (ASCT) as postconsolidation therapy for patients with myelodysplastic …

Interferon-α (IFN-α) has significantly prolonged survival in chronic myeloid leukemia (CML),
but some patients do not respond and many responses are not durable. To improve the …

Chronic myeloid leukemia (CML) has been studied intensively for many years; yet its
treatment remains problematic and its biology remains elusive. In chronic phase, the …

The treatment recommendations for chronic myelogenous leukemia (CML) are evolving
rapidly. In the past year, pegylated interferon and STI571 (Gleevec, imatinib mesylate), a Bcr …

Chronic myelogenous leukemia represents 7–20% of all leukemia cases, with a worldwide
incidence projected at less than one to two per 100,000 people. Approximately 85% of …